Arcturus Therapeutics, Inc.

This study tested a new type of COVID-19 vaccine (ARCT-2303) in over 1,500 adults who had already received a COVID-19 vaccine. Some participants got the COVID vaccine and the flu shot at the same time, while others got the COVID vaccine alone. The goal was to see how well the vac…

This early-stage study tested three new self-amplifying RNA vaccines against COVID-19 in 72 healthy adults, some already vaccinated and some not. The main goal was to check safety and how well the vaccines triggered an immune response. Results help researchers decide which vaccin…

This early-stage study tested a new type of seasonal flu vaccine called ARCT-2138, which uses self-amplifying mRNA technology to potentially provide stronger protection. Researchers gave the vaccine to 139 healthy adults aged 18-49 and 65-85 to check for side effects and measure …

This early-stage study tested a new self-amplifying mRNA vaccine (ARCT-2304) designed to protect against pandemic influenza in 212 healthy adults aged 18-80. Participants received either two doses of the experimental vaccine or one dose of a licensed flu vaccine plus a placebo. R…